Press Release
January 26, 2023

Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches

The London Life Sciences team advised Grey Wolf Therapeutics on their $49 million Series B funding round.

The round was co-led by Pfizer Ventures and Earlybird Venture Capital, and also included investment from new investors Oxford Science Enterprises and British Patient Capital and existing investors Canaan and Andera Partners.

Grey Wolf Therapeutics is a UK and Australian-based drug discovery and development biotechnology company spearheading a new therapeutic approach in immuno-oncology. Proceeds from the financing will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens.

The Goodwin Team was led by Andrew Harrow and Richard Bloomfield.

For additional details, see Grey Wolf Therapeutics’ press release.